A Tipping Point in Cancer Research
Celebrating Extraordinary Progress

SCIENTISTS, RESEARCH ORGANIZATIONS AND THE NATIONAL CANCER INSTITUTE ALL AGREE: we are at a tipping point in cancer research. The convergence of knowledge from across the spectrum of cutting-edge science combined with powerful new technologies has created a deeper understanding of cancers and advanced our ability to detect and treat these diseases earlier and more effectively.

IN THIS NEW ERA OF ACCELERATED PROGRESS, it is more important than ever that we support creative young scientists who can harness the momentum of the past decade to transform the way we prevent, detect, and treat cancer. The Damon Runyon Cancer Research Foundation is playing a central role by funding groundbreaking basic and clinical cancer research. In the past year, our brilliant young scientists:

- led studies resulting in FDA approval of two new drugs for advanced melanoma: Yervoy, an immunotherapy, and Zelboraf, a targeted therapy
- reported the success of a novel immunotherapy for pancreatic cancer
- completed the first genome sequencing of multiple myeloma and medulloblastoma
- established the link between changes in cell metabolism and brain tumor development
- developed a new understanding of how inflammation leads to drug resistance in cancer cells

THEIR INNOVATIVE CONTRIBUTIONS HAVE BEEN WIDELY RECOGNIZED:

- 2 Damon Runyon scientists were included in Science magazine’s Insights of the Decade, which listed “10 insights that have changed science since the dawn of the new millennium.”
- 2 Damon Runyon alumni were elected to the National Academy of Sciences (the science “Hall of Fame”), bringing Damon Runyon's total to 61.
- William R. Sellers, MD, Board Member and former Clinical Investigator, was appointed by President Obama to the National Cancer Advisory Board.
- Elaine V. Fuchs, PhD, Board Member and former Fellow, received the prestigious Albany Medical Center Prize.
- Current Innovator Muneesh Tewari, MD, PhD, was awarded a Presidential Early Career Award for Scientists and Engineers.
A Tipping Point in Cancer Research
A Time to Act

IT IS CRITICAL THAT WE SEIZE THIS MOMENT AND ACT ON THE EXTRAORDINARY PROGRESS OF THE PAST YEAR AND THE PAST DECADE. That is why the Damon Runyon Cancer Research Foundation is increasing its investment. In the past year, we awarded $10.2 million in new scientific grants and funded 122 scientists at 41 institutions in 17 states.

WE ALSO LAUNCHED A NEW INITIATIVE, THE CANCER BREAKTHROUGH FUND, to invest in 100 of the most brilliant young cancer researchers. We believe that these innovative minds, with their audacity and unfettered creativity, are the key to building on recent gains and translating discoveries into solutions.

Our goal is to raise a fund of $50 million over the next five years that we will put to work as rapidly as possible to support 50 Damon Runyon-Rachleff Innovators focused on high-risk, high-reward discovery and 50 Damon Runyon Clinical Investigators committed to bringing new therapies to cancer patients. The inaugural event in January in Menlo Park, California, raised $1.6M in new commitments for this bold new effort.

Accelerating Cancer Cures, a part of the Cancer Breakthrough Fund, is an historic collaboration of the biopharmaceutical industry, academia and Damon Runyon formed to address the critical shortage of high-quality clinical investigators. This new model for collaboration will increase resources to support young clinical researchers, rebuilding the ranks of those who have the potential to make cutting-edge breakthroughs in cancer treatments, translating science into cures. Its charter members have already pledged $5.1 million and include:

www.damonrunyon.org/accelerate

100% OF ALL DONATIONS FUND CANCER RESEARCH

All administrative and fundraising expenses are paid through Damon Runyon Broadway Tickets and our endowment.
Every new discovery that our young scientists make is directly linked to your support, and we are immensely grateful for the generosity of all of our donors. Thanks to you, Damon Runyon raised nearly $10 million and received more than $1.6 million in bequests in Fiscal Year 2011.

The Damon Runyon 5K at Yankee Stadium raised $400,000 in August 2010, drawing a capacity crowd of 4,000 participants. A special thanks to Walgreens, UniLever/White Rose, 24 Hour Fitness, New York Daily News, NBC4, SiriusXM, Poland Spring and Utz for their sponsorship.

New donors, including the Jake Wetchler Foundation for Innovative Pediatric Cancer Research and the Richard A. Lumsden Foundation, committed to sponsoring individual Damon Runyon scientists.

Damon Runyon Broadway Tickets continues to offer premium seats to the best shows in town like The Book of Mormon. Thanks once again to the Shubert Organization, Nederlander Productions, Jujamcyn Theaters and Disney Theatrical Productions for making this program possible.

Learn more at www.damonrunyon.org/broadway
Damon Runyon Award Programs

DAMON RUNYON FELLOWSHIP AWARD
Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be mentored by established investigators in leading research laboratories across the country.

Three-Year Award
Basic Scientists: $156,000
Physician-Scientists: $186,000

DALE F. FREY AWARD FOR BREAKTHROUGH SCIENTISTS
Supports a select few Damon Runyon Fellows who have greatly exceeded the Foundation’s highest expectations. This additional investment in these exceptional individuals is to help catapult their research careers and their impact on cancer.

Two-Year Award: $200,000
This program was created to honor Dale F. Frey, retired Chairman of the Damon Runyon Board of Directors, in recognition of his sixteen years of visionary leadership.

DAMON RUNYON-RACHELLEFF INNOVATION AWARD
Supports the next generation of exceptionally creative thinkers with high-risk, high-reward ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

Three-Year Award: $450,000
This program is possible through a founding grant from Andrew and Debra Rachleff, and the support of the Island Outreach Foundation.

DAMON RUNYON CLINICAL INVESTIGATOR AWARD
Supports early career physician-scientists conducting patient-oriented research. The goal of this innovative program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

Three-Year Award: $450,000 plus up to $100,000 for medical school loan repayment

CONTINUATION GRANT
Supports Damon Runyon Clinical Investigators who are approaching the end of their original three-year awards and need extra time and funding to complete a promising avenue of research or initiate/continue a clinical trial.

Two-Year Award: $300,000
This program is possible through the support of the William K. Bowes, Jr., Foundation, and Connie and Bob Lurie.

Damon Runyon Fellowship Award Committee

CHAIR
Daniel E. Gottlieb, PhD
Member, Basic Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

VICE CHAIR
Lynn Conley, PhD
Professor of Genetics, Cell Biology and Molecular, Cellular and Developmental Biology
Department of Genetics
Yale University School of Medicine
New Haven, Connecticut

David P. Bartel, PhD
Investigator, Howard Hughes Medical Institute
Professor of Biology
Massachusetts Institute of Technology

Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

Frederick R. Cross, PhD
Professor
Laboratory of Yeast Molecular Genetics
The Rockefeller University
New York, New York

Andrew G. Dillin, PhD
Investigator, Howard Hughes Medical Institute
Associate Professor and Pioneer Developmental Chair
Molecular and Cell Biology Lab
Salk Institute for Biological Studies
La Jolla, California

Robert N. Eisenman, PhD
Member, Basic Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Sankar Ghosh, PhD
Silverstein and Hutt Family Professor of Microbiology and Immunology
Chair, Department of Microbiology and Immunology
Columbia University
New York, New York

B. Kip Lin Guy, PhD
Chairman, Department of Chemical Biology and Therapeutics
St. Jude Children’s Research Hospital
Memphis, Tennessee

Thomas S. Hays, PhD
Professor, Department of Genetics
Cell Biology and Development
University of Minnesota
Minneapolis, Minnesota

Tyler Jacks, PhD
Investigator, Howard Hughes Medical Institute
Director, David H. Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, Massachusetts

Ligia Lao, PhD
Investigator, Howard Hughes Medical Institute
Professor, Department of Biological Sciences
Stanford University
Stanford, California

Terry Magnuson, PhD
Sarah Graham Kemen Professor
Chair, Department of Genetics
Vice Dean for Research, School of Medicine
Program Director, Cancer Genetics
Lincoln Comprehensive Cancer Center
University of North Carolina
School of Medicine
Chapel Hill, North Carolina

Philippa C. Marrack, FRS, PhD
Investigator, Howard Hughes Medical Institute
Member, Department of Immunology
National Jewish Medical and Research Center
Denver, Colorado

David J. McConkey, PhD
Director of Urologic Research
Professor, Departments of Urology and Cancer Biology
M D Anderson Cancer Center
The University of Texas
Houston, Texas

Michael T. McLain, PhD
Associate Professor
Department of Microbiology and Immunology
Diabetes Center
University of Colorado
Boulder, Colorado

Richard E. Heckert Professor of Chemistry
University of Illinois, Urbana-Champaign
Urbana, Illinois

Amita Sehgal, PhD
Investigator, Howard Hughes Medical Institute
John Harr Musser Professor
Department of Neuroscience
University of Pennsylvania
School of Medicine
Philadelphia, Pennsylvania

Brent R. Stockwell, PhD
Associate Professor
Department of Biological Sciences and Department of Chemistry
Columbia University
New York, New York

Wilfred A. van der Donk, PhD
Investigator, Howard Hughes Medical Institute
Richard E. Heckert Professor of Chemistry
University of Illinois, Urbana-Champaign
Urbana, Illinois

Terry A. Van Dyke, PhD
Chief, Mouse Cancer Genetics Program
Center for Cancer Research
Director, Center for Advanced Preclinical Research
National Cancer Institute at Frederick
Frederick, Maryland

Johannes Walter, PhD
Professor
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts
Damon Runyon Fellowship Awards

**CALIFORNIA**

\[9\] Damon Runyon Fellow with Jeanne L. Sznajder, PhD

"Epigenetic regulation of X-chromosome silencing in noncoding RNAs" with Barbara J. Wold, PhD, California Institute of Technology, Pasadena

James C. Scott, PhD, Brown University School of Medicine, Providence

"Function and genomic stability of 5-hydroxymethylcytosine" with Anjana Rao, PhD, La Jolla Institute for Allergy and Immunology, La Jolla

Gabriel C. Lander, PhD, Merck Research Laboratories

"Structural roles of enzymes and substrates in the construction of a microtube platform that catalyzes APC-directed ubiquitination of checkpoint protein p53" with Eva Nogales, PhD, Lawrence Berkeley National Laboratory, Berkeley

Shariel L. Sandall, PhD

"Mechanisms regulating maintenance of stem cells and the niches in Drosophila" with D. Leanne Jones, PhD, Salk Institute for Biological Studies, La Jolla

\[10\]

Hua Lu, PhD

"The John W. M. and Lila C. Fleck Professor at the Scripps Research Institute, La Jolla"

Benjamin R. Myers, PhD

"Analyzing the mechanism of Hobgoblin signaling regulation by the Patched proteins" with Philip A. Beachy, PhD, Stanford University School of Medicine, Stanford

Jason A. Renter, PhD

"Characterizing non-coding RNA interactions with dominant regulators of neuronal differentiation" with Michael P. Snyder, PhD, Stanford University School of Medicine, Stanford

Volker Schwikowski, PhD

"A single-molecule study of factors TFIIH and TFIIJ during transcriptional elongation by RNA polymerase II" with Steven M. Block, PhD, Stanford University School of Medicine, Stanford

Alexander Wurd, PhD

"Howard Hughes Medical Institute Fellow in "Immunostaining of cancer signaling pathways in Drosophila olfactory system development" with Leon Luo, PhD, Stanford University School of Medicine, Stanford

Yang Guang, PhD

"Howard Hughes Medical Institute Fellow in "Neural communication dynamics and thresholds in cell cycle commitment" with Tobias Meyer, PhD, Stanford University School of Medicine, Stanford

Leon Y. Chu, PhD

"Howard Hughes Medical Institute Fellow in "Determining the mechanism of stress-induced ribosomal protein mRNA degradation" with Jonathan S. Weissman, PhD, University of California, Berkeley

Yumi Kim, PhD

"Howard Hughes Medical Institute Fellow in "Identification of the signaling cascades regulating metastatic chromosomal dynamics" with Abby D. Dang, PhD, University of California, Berkeley

Maurizio Righini, PhD

"Merck Fellow in "Single molecule translation control" with Carlos Restrepo, PhD, University of California, Berkeley

Lars C. Skarhek, PhD

"Robert Black Fellow in "In vivo identification of nucleolar regulators of epithelial-mesenchymal transitions" with David D’Alpa, PhD, University of California, Berkeley

Adam de la Zerda, PhD

"Imaging cancer genomes with functionalized carbon nanotubes" with Carolyn R. Bertozzi, PhD, University of California, Berkeley

\[10\]

Orkan Akın, PhD

"Howard Hughes Medical Institute Fellow in "Live imaging of neuronal targeting in the Drosophila visual system with 2-photon microscopy" with S. Lawrence Zipser, PhD, University of California, Los Angeles

Christopher J. Hale, PhD

"Howard Hughes Medical Institute Fellow in "Understanding how one gene multiple yeast links RNA replication, repair and translation" with Steven E. Jacobson, PhD, University of California, Los Angeles

Christopher S. Campbell, PhD

"Cordelia in the soma and the somatopleural complex by post-translational modification" with Arash D. Doosti, PhD, University of California, San Francisco

Kimberley Evason, MD, PhD

"Rutland Cancer Research Fellow in "Hepatic stellate cell development and role in carcinogenesis" with Dider Y. Stainier, PhD, Stanford University School of Medicine, Stanford

Xi Huang, PhD

"Howard Hughes Medical Institute Fellow in "Functional maintenance of potassium channel KAG1 in medulloblastoma" with Lily Y. Yan, PhD, University of California, San Francisco

Calvin H. Jian, PhD

"Howard Hughes Medical Institute Fellow in "Immunostaining of cancer signaling pathways in Drosophila olfactory system development" with Leon Luo, PhD, Stanford University School of Medicine, Stanford

Ying Lu, PhD

"Howard Hughes Medical Institute Fellow in "Immunostaining of cancer signaling pathways in Drosophila olfactory system development" with Leon Luo, PhD, Stanford University School of Medicine, Stanford

\[10\]

\[10\]}

Lilian Lu, PhD

"Howard Hughes Medical Institute Fellow in "Bifurcation and functional studies of G protein-coupled receptors" with Stephen C. Harrison, PhD, Harvard Medical School, Boston

Kristin A. Krueger, PhD

"Howard Hughes Medical Institute Fellow in "Regulation and mechanism of pri-miRNA processing" with Joan T. Steitz, PhD, Yale University, New Haven

想起了continue in the next image.
matory stimulus” with Kevin M. Haigis, PhD.

“Modulation of Notch signaling to control tumor microenvironment” with Tyler Jacks, PhD, Massachusetts Institute of Technology, Cambridge.

David Botstein, PhD
Professor, Department of Molecular Biology and Genetics
The Johns Hopkins University, Baltimore, Maryland

Mark M. Davis, PhD
Investigator, Howard Hughes Medical Institute
Director of the Stanford Institute for Immunity, Transplantation and Infection
Stanford University School of Medicine, Stanford, California

Napoileone Ferrara, MD
Genentech Fellow
Tumor Biology and Angiogenesis
Genentech, Inc.
South San Francisco, California

Sanjiv Sam Gambhir, MD, PhD
Investigator, Howard Hughes Medical Institute
Professor
Cold Spring Harbor Laboratory
Menlo Park, California

Kevan M. Shokat, PhD
Director, The Ludwig Center for Cancer Genetics and Therapeutics
Professor of Oncology and Director
The Johns Hopkins University
Kimmel Cancer Center
Baltimore, Maryland

Baltimore, Maryland

Dante F. Frey Award for Breakthrough Scientists

Ken Cadwell, PhD
“Characterization of mice deficient in autophagy protein Atg5”
New York University School of Medicine, New York

L. Stirling Churchman, PhD
“Visualizing global transcription in vivo at nucleosome resolution”
Harvard Medical School, Boston, Massachusetts

Damon Runyon-Rachleff Innovation Award

Joshua C. Mungur, PhD
“Elucidating mechanisms of oncogenic metabolic manipulation” at the University of Rochester, Rochester

Texas

Benjamin P. Tu, PhD
“A novel strategy for attacking tumors based on the identification of a fundamental carbon-source signal driving cell growth” at the University of Texas Southwestern Medical Center, Dallas

Washington

Muneesh Tewari, MD, PhD
“Cancer detection in ‘pre-diagnosis’ brain tissue via microplate-associated RNAs” at the Fred Hutchinson Cancer Research Center, Seattle

12

The Damon Runyon Cancer Research Foundation

Damaso Marquez, MD
Damon Runyon-Rachleff Innovation Award Committee
Damon Runyon Clinical Investigator Award Committee

CHAIR
Richard J. O’Reilly, MD
Chair, Department of Pediatrics
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan-Kettering Cancer Center
New York, New York

Frederick R. Appelbaum, MD
Director, Clinical Research Division
Member, Fred Hutchinson Cancer Research Center
Head, Division of Medical Oncology
University of Washington School of Medicine
Seattle, Washington

Joseph B. Bertino, MD
Chief Scientific Officer
The Cancer Institute of New Jersey
Interim Director, The Stem Cell Institute
of New Jersey
University Professor of Medicine and Pharmacology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

David P. Carbone, MD, PhD
Harkle Moses Chair in Cancer Research
Director, Specialized Program of Research Excellence in Lung Cancer
Ingram Professor of Cancer Research
Professor of Medicine and Cancer Biology
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Dennis A. Carlson, MD
Professor Emeritus
Department of Medicine
Moore Cancer Center
University of California, San Diego
La Jolla, California

Bruce A. Chabner, MD
Clinical Director
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

PatriciA G. Ganz, MD
Professor, Schools of Medicine and Public Health
Director, Division of Cancer Prevention and Control Research
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Philip D. Greenberg, MD
Director, Immunology Program
Member, Fred Hutchinson Cancer Research Center
Professor of Medicine and Immunology
University of Washington
Seattle, Washington

Hedvig Hricak, MD, PhD
Chair, Department of Radiology
Carroll and Milton Petrie Chair
Memorial Sloan-Kettering Cancer Center
New York, New York

William G. Kaolin, Jr., MD
Investigator, Howard Hughes Medical Institute
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Drew M. Pardoll, MD, PhD
Director, Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Abshoff Professor of Oncology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

David R. Pisera-Worms, MD, PhD
Director, Molecular Imaging Center
Professor of Developmental Biology and Radiology
Washington University School of Medicine
St. Louis, Missouri

Kornelia Polyak, MD, PhD
Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Micheal D. Prados, MD, FACP
Professor in Residence of Neurological Surgery
Charles R. Wilson, MD, Endowed Chair
Director of Translational Research
Department of Neurological Surgery
University of California, San Francisco
San Francisco, California

Leslie L. Robinson, PhD
Member, St. Jude Faculty
Chair, Epidemiology and Cancer Control
Associate Director for Cancer Prevention and Control Center
St. Jude Children’s Research Hospital
Memphis, Tennessee

Louise C. Strong, MD
Sue and Radcliffe Killam Chair
Professor of Cancer Genetics
Chief, Section of Clinical Cancer Genetics
M.D. Anderson Cancer Center
The University of Texas
Houston, Texas

David A. Williams, MD
Chief, Division of Hematology/Oncology
Director, Translational Research for Children’s Hospital Boston
Dana-Farber Cancer Institute
Leland Fikes Chair of Pediatrics
Harvard Medical School
Boston, Massachusetts

N. Lynn Henry, MD, PhD
Lilly Clinical Investigator
“Pain processing pathway analysis in aromatase inhibitor-associated musculoskeletal syndrome” with Daniel F. Hayes, MD, University of Michigan, Ann Arbor

MINNESOTA
Andrew L. Feldman, MD
“Investigation of HIF-1 as a therapeutic target in T-Cell lymphomas” with Stephen M. Ansell, MD, PhD and Almeter Dogan, MD, PhD, Mayo Clinic, Rochester

CALIFORNIA
Jean Y. Tang, MD, PhD
“Mechanisms of acquired resistance to Hedgehog pathway inhibitors in basal cell carcinomas” with Philip A. Reachy, MD, PhD, and Ervin H. Epstein, MD, Stanford University, Stanford

CONNECTICUT
Tobias J.E. Corling, MD, PhD
Doris Duke-Damon Runyon Clinical Investigator
“Molecular genetics of endocrine tumor disease” with Richard P. Lifton, MD, and Robert Udelsman, MD, MRA, Yale University School of Medicine, New Haven

ILLINOIS
Vu H. Nguyen, MD
August M. Walsche, MD
Clinical Investigator
“Organ-specific regulatory T cells as a targeted therapy for graft-versus-host disease” with Thomas F. Gajewski, MD, PhD, The University of Chicago, Chicago

MICHIGAN
N. Lynn Henry, MD, PhD
Lilly Clinical Investigator
“Pain processing pathway analysis in aromatase inhibitor-associated musculoskeletal syndrome” with Daniel F. Hayes, MD, University of Michigan, Ann Arbor

UTAH
Joshua D. Schiffman, MD
“Microsatellite length and insertion signaling as risk factors for Ewing’s Sarcoma” with Stephen L. Lessnick, MD, PhD, University of Utah, Salt Lake City

Damon Runyon Clinical Investigator Award Continuation Grants

COLORADO
Douglas K. Graham, MD, PhD
Novartis Clinical Investigator
“Novel biologically targeted therapy against the Mer receptor tyrosine kinase in the treatment of pediatric ALL” with James V. DeGregori, PhD, and Sue Gull Eickhardt, PhD, University of Colorado Denver, Aurora

MASSACHUSETTS
Rachael A. Clark, MD, PhD
“Reversing immune evasion in human aqueous cell carcinomas of the skin” with Thomas S. Kupper, MD, Brigham and Women’s Hospital, Boston

Andrew T. Chan, MD, MPH
“Molecular imaging of colorectal neoplasia” with Charles S. Fuchs, MD, MPH, and Ralph Weissleder, MD, PhD, Massachusetts General Hospital, Boston

NEW JERSEY
Vassiliki Karanatz, MD, PhD
“Autotherapies as a therapeutic target in breast cancer treatment” with Robert S. DiPaola, MD, UMDNJ/Robert Wood Johnson Medical School, New Brunswick

NEW YORK
Igor Matsuhashi, MD, PhD
Genoa Family Clinical Investigator
“Implementing and imaging epigenetic based differential therapy for solid tumors” with Carlos Cordon-Cardo, MD, PhD, Columbia University, New York

WASHINGTON
Colleen S. Delaney, MD, MSc
Novartis Clinical Investigator
“Nexipt –mediated ex vivo expansion of cord blood progenitors for hematopoietic cell transplantation” with Erwin D. Bernstein, MD, and Frederic R. Apelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle

 Foundations for Cancer Research

Elake A. Mostaghel, MD, PhD
Genentech Clinical Investigator
“Defining and exploiting molecular mechanisms of androgen metabolism for prostate cancer therapy” with Peter S. Nelson, MD, Fred Hutchinson Cancer Research Center, Seattle

The Continuation Grant Program is supported by the William K. Bowes, Jr. Foundation, and Connie and Bob Lurie.
Named Awards

The following awards are funded by dedicated supporters of the Damon Runyon Cancer Research Foundation who have generously endowed an award in perpetuity or sponsored an individual Damon Runyon scientist:

**FELLOWS**

*Amgen Fellow*
Costas A. Lyssiotis, PhD
Beth Israel Deaconess Medical Center
Boston, Massachusetts

*Howard Hughes Medical Institute Fellow*
Jared T. Nordman, PhD
Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

*Robert A. Lanza Foundation Investigator*
August M. Watanabe, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

*Robert Wood Johnson Foundation Investigator*
Vu H. Nguyen, PhD
The University of Chicago
Chicago, Illinois

*Robert Whetzel Foundation Investigator*
Raffaella Sordella, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

*A named award is funded by the generous support from Eli Lilly and Genentech, Inc.; Merck and Company; Novartis Pharmaceuticals Corporation; and Pfizer, Inc.*

Please refer to page 14 for a list of those who hold this distinction.

**INNOVATORS**

*Island Outreach Foundation Innovator*
Vu H. Nguyen, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

*In perpetuity*
Financial Summary
Fiscal Year 2011

AS IN PREVIOUS YEARS, the financial activities of the Damon Runyon Cancer Research Foundation were audited by McGladrey and Pullen, LLP. For our complete audited financial statements, please visit our website at www.damonrunyon.org.

Overall Financial Health
SUMMARY OF BALANCE SHEETS
The Damon Runyon Cancer Research Foundation remained fiscally strong in FY 2011. Thanks to our donors, our revenues grew, enabling us to expand our scientific program funding.

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Assets</td>
<td>$92,257,373</td>
<td>$106,487,205</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$15,513,605</td>
<td>$17,214,923</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$76,743,768</td>
<td>$89,272,282</td>
</tr>
</tbody>
</table>

Where Our Money Goes
SUMMARY OF OPERATING EXPENSES

Total Operating Expenses: $13.8 Million

Where Our Support Comes From

Total Operating Revenue: $15.1 Million

“The challenge for cancer is still strong, but there is new progress being made. The science is complex and demanding, but I think it’s really going to pay off very handsomely. We’re at this kind of tipping point for cancer research, where we can truly start thinking about how to harness all of this knowledge—medical, biomedical, treatment—to prevent disease entirely or intercept it earlier.”

ELIZABETH H. BLACKBURN, PhD
Damon Runyon-Rachleff Innovation Award Committee Member
Professor of Biology and Physiology
University of California, San Francisco

“We are entering an exciting and unprecedented new era in translational cancer research. Basic lab studies and new genome-scale technologies are creating optimism that we can actually understand the biological complexity in different patients’ tumors. We have already seen successes against cancers that were considered incurable 5 years ago (for example, multiple myeloma, advanced prostate cancer, and melanoma). These efforts are completely changing the way we do cancer research: the new science is being performed by highly collaborative, multi-disciplinary teams of basic and clinical researchers in close coordination with industrial partners. We have never been this excited or confident about our ability to have major, transformative impact on cancer mortality.”

DAVID J. McCONKEY, PhD
Damon Runyon Fellowship Award Committee Member
Director of Urological Research
Professor of Cancer Biology and Urology
University of Texas MD Anderson Cancer Center

“It’s an incredibly important year in realizing the promises of new innovation in cancer research. For the first time, the government reported that a patient diagnosed with cancer has a two-thirds likelihood of being alive and cancer-free five years later. That is a great accomplishment in a generation. The excitement going forward is that we can combine new approaches—turning off genes that cause cancer while hiring the immune system to clean up the rest of the damage—and turn them into a cure.”

CRAIG B. THOMPSON, MD
President and Chief Executive Officer
Memorial Sloan-Kettering Cancer Center

“DAMON RUNYON HAS RECEIVED AN OUTSTANDING 4 STARS from Charity Navigator, indicating that the Foundation “exceeds industry standards and outperforms most charities in its Cause.”